Healthcare provider profile · identity verified

Danielle L Pellow, MD

Internal Medicine · AMES, IA · NPI 1023329026

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	561	121
Atorvastatin Calcium	Atorvastatin Calcium	474	124
Omeprazole	Omeprazole	296	69
Amlodipine Besylate	Amlodipine Besylate	269	67
Lisinopril	Lisinopril	204	48
Gabapentin	Gabapentin	183	43
Rosuvastatin Calcium	Rosuvastatin Calcium	174	48
Losartan Potassium	Losartan Potassium	170	52
Eliquis	Apixaban	161	21
Metoprolol Succinate	Metoprolol Succinate	139	33
Simvastatin	Simvastatin	139	37
Trazodone Hcl	Trazodone Hcl	129	29
Sertraline Hcl	Sertraline Hcl	126	32
Alendronate Sodium	Alendronate Sodium	120	32
Hydrochlorothiazide	Hydrochlorothiazide	118	31
Pantoprazole Sodium	Pantoprazole Sodium	112	28
Metformin Hcl	Metformin Hcl	111	27
Tramadol Hcl	Tramadol Hcl	107	31
Metformin Hcl Er	Metformin Hcl	91	21
Furosemide	Furosemide	89	29
Metoprolol Tartrate	Metoprolol Tartrate	81	22
Potassium Chloride	Potassium Chloride	79	25
Donepezil Hcl	Donepezil Hcl	78	13
Pravastatin Sodium	Pravastatin Sodium	73	17
Escitalopram Oxalate	Escitalopram Oxalate	71	18
Venlafaxine Hcl Er	Venlafaxine Hcl	67	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	66	28
Carvedilol	Carvedilol	65	12
Bupropion Xl	Bupropion Hcl	61	15
Allopurinol	Allopurinol	60	15
Tamsulosin Hcl	Tamsulosin Hcl	57	19
Fluoxetine Hcl	Fluoxetine Hcl	56	16
Glipizide Er	Glipizide	55	14
Alprazolam	Alprazolam	52	17
Ozempic	Semaglutide	52	suppressed
Clopidogrel	Clopidogrel Bisulfate	50	11
Hydroxyzine Hcl	Hydroxyzine Hcl	50	15
Tizanidine Hcl	Tizanidine Hcl	50	suppressed
Duloxetine Hcl	Duloxetine Hcl	49	12
Zolpidem Tartrate	Zolpidem Tartrate	49	suppressed
Mirtazapine	Mirtazapine	48	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	47	20
Montelukast Sodium	Montelukast Sodium	46	15
Quetiapine Fumarate	Quetiapine Fumarate	45	suppressed
Memantine Hcl	Memantine Hcl	42	suppressed
Pregabalin	Pregabalin	41	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	38	18
Spironolactone	Spironolactone	38	suppressed
Lorazepam	Lorazepam	37	13
Amitriptyline Hcl	Amitriptyline Hcl	35	suppressed
Cephalexin	Cephalexin	35	18
Ezetimibe	Ezetimibe	35	suppressed
Meloxicam	Meloxicam	35	suppressed
Mounjaro	Tirzepatide	34	suppressed
Latanoprost	Latanoprost	32	suppressed
Oxycodone Hcl	Oxycodone Hcl	31	12
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Risperidone	Risperidone	29	suppressed
Warfarin Sodium	Warfarin Sodium	29	suppressed
Clonazepam	Clonazepam	28	suppressed
Prednisone	Prednisone	28	25
Irbesartan	Irbesartan	27	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Synthroid	Levothyroxine Sodium	26	suppressed
Lovastatin	Lovastatin	24	suppressed
Atenolol	Atenolol	23	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	23	suppressed
Ramipril	Ramipril	23	suppressed
Fluticasone Propionate	Fluticasone Propionate	22	suppressed
Glipizide	Glipizide	21	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Primidone	Primidone	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	14
Baclofen	Baclofen	19	12
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Timolol Maleate	Timolol Maleate	18	suppressed
Azithromycin	Azithromycin	17	16
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	17	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Glimepiride	Glimepiride	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Naproxen	Naproxen	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Famotidine	Famotidine	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	15
Azelastine Hcl	Azelastine Hcl	15	suppressed
Colestipol Hcl	Colestipol Hcl	15	suppressed
Prazosin Hcl	Prazosin Hcl	15	suppressed
Rizatriptan	Rizatriptan Benzoate	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Trintellix	Vortioxetine Hydrobromide	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	12
Celecoxib	Celecoxib	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Nystatin	Nystatin	14	11
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Anastrozole	Anastrozole	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Methylprednisolone	Methylprednisolone	13	12
Nadolol	Nadolol	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Pen Needle	Pen Needle, Diabetic	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Estradiol	Estradiol	12	suppressed
Methscopolamine Bromide	Methscopolamine Bromide	12	suppressed
Pulmicort Flexhaler	Budesonide	12	suppressed
Topiramate	Topiramate	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error